Pharmacogenomics: Unlocking the Genetic Basis of Drug Response for Precision Medicine

[{“box”:0,”content”:”n[if 992 equals=”Open Access”]n

n

n

n

Open Access

nn

n

n[/if 992]n[if 2704 equals=”Yes”]n

n

Notice

nThis is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.n

n[/if 2704]n

n

Year : 2025 [if 2224 equals=””]05/09/2025 at 9:38 PM[/if 2224] | [if 1553 equals=””] Volume : 12 [else] Volume : [/if 1553] | [if 424 equals=”Regular Issue”]Issue : [/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] 02 | Page :

n

n

nn

n

n

n

    By

    n

    [foreach 286]n

    n

    Ankita Pramod Chaudhari, Nandini Rajendra Jadhav, Bhagyashri Ambalal Patil, Sujata Sanjaysing Girase,

    n t

  • n

    n[/foreach]

    n

n[if 2099 not_equal=”Yes”]n

    [foreach 286] [if 1175 not_equal=””]n t

  1. Assistant Professor, Assistant Professor, Assistant Professor, Assistant Professor, Department of Pharmaceutics, S.V.S’s Dadasaheb Rawal Pharmacy College, Mandal Road, Dondaicha, Tal- Shindhkheda; Dist- Dhule, Department of Quality Assurance, S.V.S’s Dadasaheb Rawal Pharmacy College, Mandal Road, Dondaicha, Tal- Shindhkheda; Dist- Dhule, Department of Pharmaceutics, P.S.G.V.P.M’s College of Pharmacy, District Nandurbar, Shahada, Department of Pharmaceutical Chemistry, Shram Sadhana Bombay Trust’s Institute of Pharmacy, Bambhori, Jalgaon, Maharashtra, Maharashtra, Maharashtra, Maharashtra, India, India, India, India

    2. n[/if 1175][/foreach]

n[/if 2099][if 2099 equals=”Yes”][/if 2099]n

n

Abstract

n

Edit

n

nPharmacogenomics, a fusion of pharmacology and genomics, explores how genetic variations influence individual responses to medications. This field is revolutionizing modern medicine by moving away from a one-size-fits-all approach toward personalized treatment strategies. By identifying specific genetic markers, pharmacogenomics aims to enhance drug efficacy, minimize adverse drug reactions, and improve overall patient outcomes. Key methodologies in this discipline include candidate gene analysis, genome-wide association studies (GWAS), and haplotype analysis, all of which contribute to understanding the genetic basis of drug response variability. Pharmacogenomics is also transforming drug development by facilitating target identification, optimizing clinical trial design, and enabling more precise therapeutic interventions. Despite significant progress, several barriers—scientific, economic, legal, and commercial—continue to challenge its widespread clinical implementation. Additionally, the integration of artificial intelligence has accelerated pharmacogenomic research by enabling large-scale data analysis and predictive modeling. Looking forward, the continued advancement of this field holds promise for safer, more effective, and cost-efficient healthcare through the development of precision medicine.nn

n

n

n

Keywords: Pharmacogenomics, genetic variations, drug efficacy, cost-efficient, precision medicine.

n[if 424 equals=”Regular Issue”][This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

n

[/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue under section in Research & Reviews: A Journal of Drug Design & Discovery (rrjoddd)][/if 424][if 424 equals=”Conference”]This article belongs to Conference [/if 424]

n

n

n

How to cite this article:
nAnkita Pramod Chaudhari, Nandini Rajendra Jadhav, Bhagyashri Ambalal Patil, Sujata Sanjaysing Girase. [if 2584 equals=”][226 wpautop=0 striphtml=1][else]Pharmacogenomics: Unlocking the Genetic Basis of Drug Response for Precision Medicine[/if 2584]. Research & Reviews: A Journal of Drug Design & Discovery. 05/09/2025; 12(02):-.

n

How to cite this URL:
nAnkita Pramod Chaudhari, Nandini Rajendra Jadhav, Bhagyashri Ambalal Patil, Sujata Sanjaysing Girase. [if 2584 equals=”][226 striphtml=1][else]Pharmacogenomics: Unlocking the Genetic Basis of Drug Response for Precision Medicine[/if 2584]. Research & Reviews: A Journal of Drug Design & Discovery. 05/09/2025; 12(02):-. Available from: https://journals.stmjournals.com/rrjoddd/article=05/09/2025/view=0

nn

n

n[if 992 equals=”Open Access”]Full Text PDF[/if 992]n

n

n[if 992 not_equal=”Open Access”]n

n

n[/if 992]n

nn

n nn

n[if 379 not_equal=””]nn

Browse Figures

n

n

n[foreach 379]

figures

[/foreach]n

n

n

n[/if 379]

n

n

Edit

n

n

n

References n

n[if 1104 equals=””]n

  1. Frueh, F. W. (2010). Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical Practice. Pharmacogenomics, 11(5), 657–660. https://doi.org/10.2217/pgs.10.46
  2. Trent, R. J. (2009). Pathology Practice and Pharmacogenomics. Pharmacogenomics, 11(1), 105–111. https://doi.org/10.2217/pgs.09.150
  3. Arendt, D., Musser, J., Baker, C. et al. The origin and evolution of cell types. Nat Rev Genet 17, 744–757 (2016). https://doi.org/10.1038/nrg.2016.127
  4. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E; 2006 Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med., 57, 119–137. https://doi.org/10.1146/annurev.med.56.082103.104724
  5. Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. AAPS J20, 4 (2018). https://doi.org/10.1208/s12248-017-0161-x
  6. Wolfgang Sadée, Zunyan Dai, Pharmacogenetics/genomics and personalized medicine, Human Molecular Genetics, Volume 14, Issue suppl_2, 15 October 2005, Pages R207–R214, https://doi.org/10.1093/hmg/ddi261
  7. T P A, M SS, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res. 2009 Oct;1(4):191-4. doi: 10.4021/jocmr2009.08.1255. 
  8. Åkerlund, E., Gudoityte, G., Moussaud-Lamodière, E. et al.The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. npj Precis. Onc.7, 111 (2023). https://doi.org/10.1038/s41698-023-00463-z 
  9. AACR Project Genie Consortium; André, F.; Arnedos, M.; Baras, A.S.; Baselga, J.; Zhang, H. 2017; AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov; 7, 818–831.
  10. Derry, J., Mangravite, L., Suver, C. et al.Developing predictive molecular maps of human disease through community-based modeling. Nat Genet 44, 127–130 (2012). https://doi.org/10.1038/ng.1089
  11. Zhou, Y.; Fujikura, K.; Mkrtchian, S.; Lauschke, 2018 V.M. Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data. Front. Pharmacol; 9,1437 https://doi.org/10.3389/fphar.2018.01437 . 
  12. Kwon JM and Goate AM; 2000 The candidate gene approach. Alchol Res Health 2000; 24(3):164-8 63.
  13. Roses, A. Pharmacogenetics and the practice of medicine. Nature405, 857–865 (2000). https://doi.org/10.1038/35015728
  14. Johnson, J.A. Drug Target Pharmacogenomics. Am J Pharmacogenomics1, 271–281 (2001). https://doi.org/10.2165/00129785-200101040-00004
  15. Kuznetsov, V., Lee, H.K., Maurer-Stroh, S. et al. How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst 1, 2 (2013). https://doi.org/10.1186/2047-2501-1-2
  16. Sliwoski G, Kothiwale S, Meiler J, et al. 2014; Computational methods in drug discovery. Pharmacol Rev; 66:(1) 334–395 https://doi.org/10.1124/pr.112.007336
  17. Luo, Y., Zhao, X., Zhou, J. et al.A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun8, 573 (2017). https://doi.org/10.1038/s41467-017-00680-8
  18. Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery: Although the evolution of ‘‐omics’ methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process. EMBO reports. 2004 Sep 1;5(9):837-42. https://doi.org/10.1038/sj.embor.7400236  
  19. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British journal of pharmacology. 2011 Mar;162(6):1239-49. https://doi.org/10.1111/j.1476-5381.2010.01127.x
  20. Cully M. Target validation: Genetic information adds supporting weight. Nat Rev Drug Discov. 2015 Aug;14(8):525. doi: 10.1038/nrd4692. 
  21. Thomsen, S.K., Gloyn, A.L. Human genetics as a model for target validation: finding new therapies for diabetes. Diabetologia60, 960–970 (2017). https://doi.org/10.1007/s00125-017-4270-y
  22. Mestan, K.K., Ilkhanoff, L., Mouli, S. et al.Genomic sequencing in clinical trials. J Transl Med9, 222 (2011). https://doi.org/10.1186/1479-5876-9-222 
  23. Scott SA. 2011; Personalizing medicine with clinical pharmacogenetics;  Genet Med; 13:(12) 987–995 https://doi.org/10.1097/GIM.0b013e318238b38c . 
  24. Klein ME, Parvez MM, Shin JG; 2017 Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. J Pharm Sci; 106:(9) 2368–2379 https://doi.org/10.1016/j.xphs.2017.04.051 . 
  25. Shabbir Ahmed, Zhan Zhou, Jie Zhou, Shu-Qing Chen, Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine, Genomics, Proteomics & Bioinformatics, Volume 14, Issue 5, October 2016, Pages 298–313, https://doi.org/10.1016/j.gpb.2016.03.008
  26. Lavezzari G, Womack AW. Industry perspectives on biomarker qualification. Clinical Pharmacology & Therapeutics. 2016 Feb;99(2):208-13 https://doi.org/10.1002/cpt.264
  1. Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008 May;5(2):149-54.  
  2. Schuck, R.N., Grillo, J.A. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling. AAPS J18, 573–577 (2016). https://doi.org/10.1208/s12248-016-9891-4
  3. Magdum CS, Velingkar VS, Gupta MK. Pharmacogenomics: The search for the Individualized Therapy. Indian Journal of pharmaceutical education and research. 2006;40(2):84. 
  4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998 Apr 15;279(15):1200-5 doi:10.1001/jama.279.15.1200. 
  5. H. Abdelhalim; 2022 Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine Front Genet, 13, Article 929736. https://doi.org/10.3389/fgene.2022.929736
  6. Iyer RK, Athreya AP, Wang L, Weinshilboum RM. Artificial Intelligence and Pharmacogenomics: A Timely Synergy for Individualizing Medicine. Advances in Molecular Pathology. 2019 Nov 1;Vol :2(1):111-8 https://doi.org/10.1016/j.yamp.2019.08.003
  7. V. Jhawat; 2023; Artificial intelligence and data science in pharmacogenomics-based drug discovery: future of medicines. Data Science for Genomics, Elsevier; pp. 85-97 https://doi.org/10.1016/B978-0-323-98352-5.00005-7
  8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5. doi: 10.1001/jama.279.15.1200. 
  9. Anup Ojha and Tanuj Joshi; 2016; A review on the role of pharmacogenomics in drug discovery and development; IJPSR; Vol. 7(9): 3587-3595.

nn[/if 1104][if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]

    2. n[/foreach]

n[/if 1104]

n

nn[if 1114 equals=”Yes”]n

n[/if 1114]

n

n

[if 424 not_equal=””][else]Ahead of Print[/if 424] Subscription Original Research

n

n

[if 2146 equals=”Yes”][/if 2146][if 2146 not_equal=”Yes”][/if 2146]n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n[if 1748 not_equal=””]

[else]

[/if 1748]n

n[if 1746 equals=”Retracted”]n

n

n

n

[/if 1746]n[if 4734 not_equal=””]

n

n

n

[/if 4734]n

n

Volume 12
[if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] 02
Received 25/04/2025
Accepted 21/06/2025
Published 05/09/2025
Retracted
Publication Time 133 Days

n

n

97

nn

n

Login

n
My IP
n

PlumX Metrics

nn

n

n

n[if 1746 equals=”Retracted”]n

[/if 1746]nnn

nnn”}]